Cargando…

Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities

Endocrine disrupting chemicals (EDCs) are ubiquitous in the environment and involve diverse chemical-receptor interactions that can perturb hormone signaling. The Organization for Economic Co-operation and Development has validated several EDC-receptor bioassays to detect endocrine active chemicals...

Descripción completa

Detalles Bibliográficos
Autores principales: Martyniuk, Christopher J., Martínez, Rubén, Navarro-Martín, Laia, Kamstra, Jorke H., Schwendt, Adam, Reynaud, Stéphane, Chalifour, Lorraine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669078/
https://www.ncbi.nlm.nih.gov/pubmed/34418449
http://dx.doi.org/10.1016/j.envres.2021.111904
_version_ 1784614712825085952
author Martyniuk, Christopher J.
Martínez, Rubén
Navarro-Martín, Laia
Kamstra, Jorke H.
Schwendt, Adam
Reynaud, Stéphane
Chalifour, Lorraine
author_facet Martyniuk, Christopher J.
Martínez, Rubén
Navarro-Martín, Laia
Kamstra, Jorke H.
Schwendt, Adam
Reynaud, Stéphane
Chalifour, Lorraine
author_sort Martyniuk, Christopher J.
collection PubMed
description Endocrine disrupting chemicals (EDCs) are ubiquitous in the environment and involve diverse chemical-receptor interactions that can perturb hormone signaling. The Organization for Economic Co-operation and Development has validated several EDC-receptor bioassays to detect endocrine active chemicals and has established guidelines for regulatory testing of EDCs. Focus on testing over the past decade has been initially directed to EATS modalities (estrogen, androgen, thyroid, and steroidogenesis) and validated tests for chemicals that exert effects through non-EATS modalities are less established. Due to recognition that EDCs are vast in their mechanisms of action, novel bioassays are needed to capture the full scope of activity. Here, we highlight the need for validated assays that detect non-EATS modalities and discuss major international efforts underway to develop such tools for regulatory purposes, focusing on non-EATS modalities of high concern (i.e., retinoic acid, aryl hydrocarbon receptor, peroxisome proliferator-activated receptor, and glucocorticoid signaling). Two case studies are presented with strong evidence amongst animals and human studies for non-EATS disruption and associations with wildlife and human disease. This includes metabolic syndrome and insulin signaling (case study 1) and chemicals that impact the cardiovascular system (case study 2). This is relevant as obesity and cardiovascular disease represent two of the most significant health-related crises of our time. Lastly, emerging topics related to EDCs are discussed, including recognition of crosstalk between the EATS and non-EATS axis, complex mixtures containing a variety of EDCs, adverse outcome pathways for chemicals acting through non-EATS mechanisms, and novel models for testing chemicals. Recommendations and considerations for evaluating non-EATS modalities are proposed. Moving forward, improved understanding of the non-EATS modalities will lead to integrated testing strategies that can be used in regulatory bodies to protect environmental, animal, and human health from harmful environmental chemicals.
format Online
Article
Text
id pubmed-8669078
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86690782022-03-01 Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities Martyniuk, Christopher J. Martínez, Rubén Navarro-Martín, Laia Kamstra, Jorke H. Schwendt, Adam Reynaud, Stéphane Chalifour, Lorraine Environ Res Article Endocrine disrupting chemicals (EDCs) are ubiquitous in the environment and involve diverse chemical-receptor interactions that can perturb hormone signaling. The Organization for Economic Co-operation and Development has validated several EDC-receptor bioassays to detect endocrine active chemicals and has established guidelines for regulatory testing of EDCs. Focus on testing over the past decade has been initially directed to EATS modalities (estrogen, androgen, thyroid, and steroidogenesis) and validated tests for chemicals that exert effects through non-EATS modalities are less established. Due to recognition that EDCs are vast in their mechanisms of action, novel bioassays are needed to capture the full scope of activity. Here, we highlight the need for validated assays that detect non-EATS modalities and discuss major international efforts underway to develop such tools for regulatory purposes, focusing on non-EATS modalities of high concern (i.e., retinoic acid, aryl hydrocarbon receptor, peroxisome proliferator-activated receptor, and glucocorticoid signaling). Two case studies are presented with strong evidence amongst animals and human studies for non-EATS disruption and associations with wildlife and human disease. This includes metabolic syndrome and insulin signaling (case study 1) and chemicals that impact the cardiovascular system (case study 2). This is relevant as obesity and cardiovascular disease represent two of the most significant health-related crises of our time. Lastly, emerging topics related to EDCs are discussed, including recognition of crosstalk between the EATS and non-EATS axis, complex mixtures containing a variety of EDCs, adverse outcome pathways for chemicals acting through non-EATS mechanisms, and novel models for testing chemicals. Recommendations and considerations for evaluating non-EATS modalities are proposed. Moving forward, improved understanding of the non-EATS modalities will lead to integrated testing strategies that can be used in regulatory bodies to protect environmental, animal, and human health from harmful environmental chemicals. Elsevier 2022-03 /pmc/articles/PMC8669078/ /pubmed/34418449 http://dx.doi.org/10.1016/j.envres.2021.111904 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Martyniuk, Christopher J.
Martínez, Rubén
Navarro-Martín, Laia
Kamstra, Jorke H.
Schwendt, Adam
Reynaud, Stéphane
Chalifour, Lorraine
Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities
title Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities
title_full Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities
title_fullStr Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities
title_full_unstemmed Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities
title_short Emerging concepts and opportunities for endocrine disruptor screening of the non-EATS modalities
title_sort emerging concepts and opportunities for endocrine disruptor screening of the non-eats modalities
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669078/
https://www.ncbi.nlm.nih.gov/pubmed/34418449
http://dx.doi.org/10.1016/j.envres.2021.111904
work_keys_str_mv AT martyniukchristopherj emergingconceptsandopportunitiesforendocrinedisruptorscreeningofthenoneatsmodalities
AT martinezruben emergingconceptsandopportunitiesforendocrinedisruptorscreeningofthenoneatsmodalities
AT navarromartinlaia emergingconceptsandopportunitiesforendocrinedisruptorscreeningofthenoneatsmodalities
AT kamstrajorkeh emergingconceptsandopportunitiesforendocrinedisruptorscreeningofthenoneatsmodalities
AT schwendtadam emergingconceptsandopportunitiesforendocrinedisruptorscreeningofthenoneatsmodalities
AT reynaudstephane emergingconceptsandopportunitiesforendocrinedisruptorscreeningofthenoneatsmodalities
AT chalifourlorraine emergingconceptsandopportunitiesforendocrinedisruptorscreeningofthenoneatsmodalities